Roche presents new data on CD20xCD3 T cell binding bispecific antibody NHL immunotherapy

Compileriver

Recently, according to foreign media reports, Roche Genentech demonstrated its research CD20xCD3 T cell binding bispecific antibodies mosunetuzumab and glofitamab, and its first CD79b antibody drug conjugate Polivy (polatuzumab vedotin) at the ASCO 2021 annual meeting.

Approximately 500,000 people are diagnosed with NHL every year worldwide, but the current treatment options are limited, and resistance to existing therapies or relapse after treatment is common

The key data of mosunetuzumab and glofitamab shown in this show include:

The phase I NP30179 study investigated increasing the dose of glofitamab in R/R NHL patients who had previously received over-pretreatment, showing successful sustained complete remission (CR) and acceptable safety

Extensive development projects of mosunetuzumab and glofitamab are also underway, including:

Phase III GO42909 trial study mosunetuzumab + lenalidomide vs.

Polivy, a drug conjugate targeting CD79b antibody, is already a treatment option for patients with R/R DLBCL and continues to show potential in a variety of combinations

The results of the Phase Ib/II GO29834 study showed that the new triple combination of Polivy with Rituxan and lenalidomide showed promising activity in the difficult-to-treat R/R DLBCL

Genentech's goal is to submit the regulatory documents for mosunetuzumab by the end of 2021, after it received the FDA's breakthrough therapy designation in June 2020

Reference source: Genentech Presents Latest Advances With Immunotherapies in Non-Hodgkin's Lymphoma